Skip to main content

Table 1 Baseline characteristics

From: Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction

 

HCM (n=51)

Control (n=25)

p value

Age, y

48 ± 14

48 ± 17

0.8

Males, n (%)

39 (76%)

18 (72%)

0.7

Body mass index, kg/m2

27.5 ± 4.9

24.1 ± 2.7

<0.001

Family history of HCM, n (%)

17 (33%)

-

 

Symptoms, n (%)

   

Chest pain

16 (31%)

-

 

Dyspnoea

28 (55%)

-

 

NYHA class I or II

51 (100%)

-

 

Presyncope

18 (35%)

-

 

Syncope

6 (12%)

-

 

Medications, n (%)

   

Beta-blocker

29 (57%)

-

 

Calcium channel blocker

10 (20%)

-

 

Resting heart rate, beats/min

60 ± 10

62 ± 9

0.6

Systolic blood pressure, mm Hg

129 ± 16

133 ± 18

0.4

Hematocrit

0.43 ± 0.04

0.42 ± 0.03

0.3

eGFR, ml/min/1.73 m2

81 ± 12

86 ± 8

0.14

  1. NYHA indicates New York Heart Association; and eGFR, estimated glomerular filtration rate.